Trial Profile

A global, randomized, placebo-controlled registration-enabling Phase 3 trial of deupirfenidone in Idiopathic pulmonary fibrosis patients

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deupirfenidone (Primary) ; Pirfenidone
Indications Idiopathic pulmonary fibrosis
Focus Registrational; Therapeutic Use
Sponsors PureTech Health

Most Recent Events

30 Jun 2022 According to a PureTech media release, the company expect topline results from the study by the end of 2023.
30 Jun 2022 Status changed from planning to recruiting, according to a PureTech media release, according to a PureTech media release.
14 Jun 2022 According to a PureTech media release, the company expect to initiate this trial later this month.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com